Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digital health solutions in cancer patients receiving systemic treatment
NCT05694013Phase 3Terminated
- Sponsor
- Roche
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in non-small cell lung carcinoma (NSCLC), Small Cell Lung Cancer (SCLC) and hepatocellular carcinoma (HCC) (3 cohorts), sponsored by Roche. Primary endpoint: Mean Difference in Change of Week 12 Value From Baseline of Participant-reported Total Symptom Interference from the MD Anderson Symptom Inventory Core Items. Started Feb 2023; status: terminated.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung carcinoma (NSCLC)Small Cell Lung Cancer (SCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05694013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694013.